How Long Does It Take for Finasteride to Work on Prostate?

Finasteride begins changing prostate tissue within weeks, but the improvements you can actually feel take longer. Most men notice meaningful symptom relief after about three to six months on the drug, and prostate volume continues shrinking for at least a year or two. The timeline depends on what outcome you’re measuring, because the hormonal shift, the physical shrinkage of the gland, and the improvement in urinary symptoms each operate on their own schedule. Understanding the sequence helps set realistic expectations and explains why doctors counsel patience with a medication that genuinely does work, just not overnight.

What Finasteride Does Inside the Prostate

Finasteride blocks an enzyme that converts testosterone into dihydrotestosterone (DHT), a more potent hormone that drives prostate growth. By cutting DHT levels in the prostate, finasteride starves the gland of its primary growth signal. Research on prostate tissue from men taking finasteride shows that this triggers a combination of cell shrinkage (atrophy) and programmed cell death (apoptosis) in the gland’s epithelial lining. These cellular changes ramp up during the first several months of treatment and then taper off as the prostate reaches a new, smaller steady state.

Tissue studies confirm what’s happening at the microscopic level. In men treated with finasteride, the rate of epithelial cell death increased several-fold compared to untreated prostates, and markers of cell death peaked during the early months of therapy before settling back down.

Laboratory models reinforce this picture: finasteride roughly halved the proportion of actively dividing prostate epithelial cells and more than tripled the rate of apoptosis in tissue grafts.

That two-pronged process, fewer new cells being born and more old cells dying, is what ultimately makes the prostate smaller. But because it relies on a slow biological turnover rather than a sudden pharmaceutical knockout, it takes months rather than days.

How Quickly the Prostate Shrinks

The landmark trial that helped finasteride earn its approval enrolled nearly 900 men and measured prostate volume over 12 months. Men taking the standard 5 mg daily dose saw roughly a 19 percent decrease in prostate size compared to placebo, along with a meaningful increase in peak urinary flow rate.

A separate two-year placebo-controlled study tracked volume longer and found a similar picture: the finasteride group shrank by about 19 percent while the placebo group actually grew by 12 percent, a gap that widened over the full study period.

⁴

Most of that shrinkage accumulates during the first six to twelve months. Prostate volume continues to decline modestly into the second year, but the steepest drop happens within the first year. Data from the large Medical Therapy of Prostatic Symptoms (MTOPS) trial showed that long-term finasteride use produced a consistent volume reduction of about 25 percent compared to placebo, regardless of whether the prostate started out relatively small or quite enlarged.

⁵

That finding matters because it means finasteride isn’t only useful for men with very large prostates. The percentage of volume lost is roughly the same across a wide range of starting sizes.

When You Actually Start Feeling Better

Volume reduction is measured on ultrasound, but what most men care about is whether they’re getting up less at night, emptying their bladder more completely, and spending less time standing at the toilet. These symptomatic improvements follow a somewhat different timeline than the volumetric changes, and they tend to lag behind the physical shrinkage by a few weeks to months.

In the two-year placebo-controlled trial, the finasteride group showed progressively improving symptom scores throughout the study, with a statistically significant difference from placebo by 24 months. In the placebo group, symptoms initially improved slightly (a common placebo effect in urological trials) but drifted back to baseline by the end of two years. Peak urinary flow rate also separated between groups, with finasteride users gaining about 1.8 ml per second more than placebo users by month 24.

⁴

A study comparing finasteride monotherapy, tamsulosin (an alpha-blocker), and the two drugs combined tracked symptom scores at three and six months. Finasteride alone produced roughly a 42 percent improvement in symptom scores by three months and about 57 percent by six months. However, the flow-rate improvement with finasteride alone was small at three months and more noticeable by six, which is consistent with the idea that the gland needs time to physically shrink before urine flow improves meaningfully.

⁶

This is one reason doctors often prescribe an alpha-blocker alongside finasteride in the early months. Alpha-blockers relax the smooth muscle in the prostate and bladder neck, providing quicker symptomatic relief while you wait for finasteride to do its slower, structural work.

The Practical Timeline at a Glance

Putting the evidence together, here’s a rough schedule of what to expect:

First 1-2 weeks: DHT levels in the prostate begin dropping, but you won’t notice anything yet.
Months 1-3: Cell death and shrinkage are actively underway in prostate tissue. Some men report modest symptom improvement, but most feel little change.
Months 3-6: Prostate volume has decreased measurably. Symptom scores typically show meaningful improvement, though urinary flow rates may still be catching up.
Months 6-12: Most of the volume reduction has occurred. Symptom relief and flow-rate improvements become more pronounced and consistent.
Year 2 and beyond: Continued modest gains. The prostate may shrink slightly further, and crucially, finasteride prevents the regrowth that would otherwise occur. Symptom improvements continue to separate from placebo.

If you’ve been taking finasteride for four to six months and feel no change at all, that’s not unusual, but it’s worth discussing with your doctor. The drug is slow by design, and the benefits of continued use extend well beyond the first year.

Preventing Surgery and Acute Retention

One of finasteride’s most clinically important effects takes years to become apparent. Enlarged prostates can eventually cause acute urinary retention, a sudden inability to urinate that sends men to the emergency room and often leads to catheterization or surgery. A four-year trial of over 3,000 men found that finasteride cut the risk of acute urinary retention by about 57 percent and reduced the likelihood of needing surgery by roughly 55 percent compared to placebo.

⁷

A pooled analysis of three separate two-year studies confirmed the same pattern: finasteride reduced the hazard of acute retention by 57 percent and the hazard of BPH-related surgery by 34 percent over two years.

⁸

These aren’t improvements you “feel” in the way symptom relief registers day to day, but they represent avoided crises. For men with moderately to significantly enlarged prostates, this prevention of downstream complications is often the strongest argument for staying on finasteride long term.

What Finasteride Does to Your PSA

PSA (prostate-specific antigen) is a blood marker used to screen for prostate cancer. Finasteride lowers PSA levels substantially, and if you don’t account for this, a misleadingly low PSA reading could mask a developing cancer. In clinical trials, 12 months of finasteride produced a median PSA drop of about 50 percent. After treatment, roughly three-quarters of men had PSA levels at or below 2.0 ng/ml, comparable to the proportion whose pretreatment PSA was at or below 4.0 ng/ml.

⁹

This roughly 50 percent reduction stabilizes after the first year or so, but it doesn’t stay fixed forever. Data from the Prostate Cancer Prevention Trial showed that the adjustment factor needed to interpret PSA in finasteride users crept up over time, from about 2 at two years to about 2.5 at seven years.

¹⁰

In plain terms: if you’ve been on finasteride for a couple of years, your doctor should roughly double your PSA reading to estimate what it would be without the drug. After several years, the multiplier edges a bit higher. Any PSA result that rises while you’re on finasteride, even if the number still looks “normal,” deserves attention. A rising PSA in the context of a drug that suppresses it can be an early signal that something else is going on.

How Finasteride Compares to Dutasteride

Dutasteride is the other 5-alpha reductase inhibitor on the market. Both drugs work by the same basic mechanism, but dutasteride blocks both type 1 and type 2 forms of the enzyme, while finasteride targets only type 2. In a real-world retrospective comparison, dutasteride achieved a somewhat larger reduction in prostate volume (about 26 percent versus about 18 percent for finasteride) and a slightly greater drop in PSA. Symptom scores improved slightly more with dutasteride as well, though the difference was modest.

¹¹

For most men, the practical difference between the two drugs is small enough that cost, insurance coverage, and side-effect profile tend to drive the choice. Dutasteride also has a much longer half-life, which means its effects linger in the body for weeks after stopping. Finasteride clears faster, which can be relevant if side effects become an issue. The onset timelines are broadly similar: both drugs take months to produce noticeable benefit, and neither offers quick relief on its own.

What Happens If You Stop

Finasteride doesn’t cure benign prostatic hyperplasia. It manages it. Once you stop, the underlying hormonal driver comes back and the prostate starts regrowing. A prospective study followed men who discontinued their 5-alpha reductase inhibitor after one year of combination therapy with an alpha-blocker. Within a year of stopping, prostate volume had increased by roughly 19 to 21 percent, and symptom scores deteriorated significantly.

¹²

Another study found that one year after stopping, the prostate had essentially returned to its pre-treatment size, restoring to about 100 percent of the reduced volume.

¹³

This regrowth isn’t surprising given the mechanism: DHT production resumes once the enzyme is no longer blocked, and the gland responds to the renewed hormonal signal. It’s a strong argument against stopping finasteride because you feel better. The improvement you’re feeling is the drug working, not the condition resolving.

Side Effects and the Question of Persistence

The most commonly discussed side effects of finasteride involve sexual function: reduced libido, erectile difficulty, and ejaculatory changes. In the large clinical trials that led to approval, these occurred in a small percentage of men and typically resolved after stopping the drug. More concerning are reports from smaller studies of persistent sexual side effects that continued long after finasteride was discontinued. One study surveyed men who had developed new sexual dysfunction while on finasteride (most of them using the lower 1 mg dose for hair loss rather than the 5 mg BPH dose) and found that the vast majority still reported symptoms an average of 40 months after stopping.

¹⁴

A follow-up assessment of a similar group found that persistent side effects were still present in 96 percent of subjects at reassessment.

¹⁵

These findings have fueled debate about a condition sometimes called “post-finasteride syndrome,” which encompasses persistent sexual, neuropsychiatric, and physical symptoms after stopping the drug. The medical community remains divided on how to characterize it. A review noted that existing studies can neither confirm nor refute the syndrome as a distinct clinical entity, but suggested that if it does occur, it may affect genetically susceptible individuals even at low doses and short durations.

¹⁶

It’s worth keeping perspective. The studies documenting persistent effects recruited men who had already experienced side effects, so the rates reported within those groups don’t represent the risk for every man who takes finasteride. Across large clinical trials, most men tolerate the drug without sexual side effects at all. Still, if you develop sexual symptoms while on finasteride, raise them with your doctor promptly rather than assuming they’ll resolve on their own.

Why Some Men Respond More Than Others

Prostate size at baseline is one factor. As noted earlier, the MTOPS trial found that finasteride produced a consistent percentage reduction regardless of starting volume, but in absolute terms, men with larger prostates lose more tissue and tend to experience greater symptomatic improvement. This is partly because a larger gland contributes more to obstruction, so shrinking it by the same fraction has a bigger functional impact.

⁵

PSA level at baseline is another practical predictor, because higher PSA generally correlates with more glandular tissue (as opposed to fibrous or muscular tissue), and finasteride’s effect is primarily on the glandular component. Men with very low PSA levels and small prostates are less likely to notice dramatic benefit, and some guidelines suggest reserving 5-alpha reductase inhibitors for men whose prostates are above a certain size threshold or whose PSA indicates significant glandular enlargement.

Age, severity of symptoms, how much of the obstruction is due to dynamic (muscular) versus static (tissue bulk) factors, and even individual variation in drug metabolism all play roles. There’s no reliable way to predict exactly how much a given person will benefit, but the broad pattern is that men with larger, more glandular prostates and higher baseline PSA levels tend to get the most out of finasteride.

Structural Changes Beyond Simple Shrinkage

Finasteride doesn’t just make the prostate smaller in a uniform way. Animal studies show that blocking DHT triggers a remodeling of the gland’s internal architecture. The epithelial cells that line the ducts become shorter and less active, the ducts themselves narrow, and the stromal tissue (the supportive framework around the ducts) actually thickens and accumulates collagen. Smooth muscle cells within the stroma undergo de-differentiation, losing some of their contractile character.

¹⁷

These structural details help explain a clinical observation: some men experience prostate shrinkage on finasteride without a proportional improvement in urinary flow. If the gland shrinks mainly on its epithelial side while the stromal framework persists or fibroses, the channel through the prostate may not open up as much as the volume reduction would suggest. It also explains why combination therapy with an alpha-blocker, which relaxes the smooth muscle component, can complement finasteride’s tissue-reducing effects so well. The two drugs address different parts of the problem.